Duke Street Bio receives FDA fast track designation for PARP1-selective inhibitor with CNS activity

Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need

Nectar Lifesciences sell API and formulations business to Ceph Lifesciences for Rs. 1,270 Cr

Dr. Jitendra Singh inaugurates 'National Biobank' at CSIR-IGIB

CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders

SPARC incorporates subsidiary ‘Genokine Biotech’

The wholly owned subsidiary will carry on the business of all types of research and development and other related services

Suraksha Diagnostic unveils Eastern India's largest genomics lab

Zota Health Care expands Davaindia network to 1,760 operational stores

Surpassing 1,000 Company Owned Company Operated stores

Asahi Kasei Pharma starts Phase III study of promising CIPN prevention therapy

ART-123 is a recombinant human thrombomodulin approved in Japan in 2008

India exports US$ 4,961 million pharmaceutical during April–May 2025: Pharmexcil

Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future

Cadila Pharmaceuticals launches Bilacad Dex Syrup

A triple-action Formula for comprehensive respiratory relief

AstraZeneca Pharma India receives permission to import Durvalumab Solution

Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy